



NEEMS HILL

Neem's Hill AB (publ)

Human Care | Animal Care

Interim report
Q3 2026





Neem's Hill AB (publ)

January - September 2026

- Net sales amounted to 9,466 kSEK (9,637)
- Profit/loss after financial items amounted to -5,486 kSEK (-5,532)
- Earnings per share amounted to -0,21 SEK (-0,24)
- Cash flow from operating activities amounted to -5,393 kSEK (-3,406)

July – September 2026

- Net sales amounted to 3,376 kSEK (3,324)
- Profit/loss after financial items amounted to -1,291 kSEK (-1,267)
- Earnings per share amounted to -0,05 SEK (-0,05)
- Cash flow from operating activities amounted to -2,470 kSEK (-1,663)

Events during the reporting period

- ChemoTech's TSE Reports 97% complete remission and stronger than expected clinical results in Equine
- Scandinavian ChemoTech AB changes name to Neem's Hill AB

Events after the reporting period

- -

Word from the CEO

The third quarter of 2026 brought continued growth in treatment kit sales within Neem's Hill's Animal Care business, reflecting greater clinical use of installed vetIQure-TSE systems and a stronger recurring revenue base. September was one of our strongest sales months to date. We continue to see significant potential to expand our customer base while helping existing clinics increase their use of TSE.

As Animal Care develops a more stable sales base, we are moving closer to a position where we can consider renewed investment in the Group's Human Care business. Our primary focus is India, where we are evaluating opportunities to advance clinical development in head and neck and breast cancer, with the pace determined by available resources and clinical partnerships.

Growing recurring revenue

Total Animal Care revenue reached kUSD 360 in the third quarter. The period included the summer months, with the majority of sales generated toward the end of the quarter. This strong finish indicates encouraging commercial momentum as we enter Q4.

Revenue from treatment kits continued to grow during the year, reflecting increased clinical use of installed vetIQure systems. As clinics gain experience with TSE and integrate it into their treatment offering, repeat kit purchases strengthen our recurring revenue base.

With more than 60 systems installed globally and over 4,500 Animal Care treatments sold since commercialization, we have an expanding foundation for further growth. Our focus remains on helping existing customers increase treatment activity while bringing TSE to new clinics.

Device sales within key accounts depend partly on the timing of larger negotiated orders, and ongoing discussions have yet to translate into the volumes we believe these relationships can generate. We continue to see substantial opportunities to expand installations within these groups, although the timing and scale of individual orders remain uncertain.

Strengthening sales and clinical support

Despite the encouraging growth in recurring revenue, we are not satisfied with the pace of sales development in either the US or our newer European markets. Our commercial results remain well below what we believe our technology and market opportunity can support. We are addressing this through sharper account prioritization, more direct engagement with clinicians and closer follow-up of sales activity, with a clear focus on translating our increased commercial capacity into new customers and sales.

The additional sales and marketing capacity introduced since June strengthens our ability to pursue new customers across North America and Europe. This includes greater

coverage of major US markets and regions such as the Midwest, alongside a dedicated sales representative for Germany, Austria and Switzerland. As these representatives develop their territories and customer relationships, we expect their contribution to sales growth to increase.

Our commercial strategy combines relationships with larger veterinary groups with direct engagement at individual clinics. We are placing greater emphasis on identifying suitable customers, establishing clinical needs and helping veterinarians integrate TSE into their standard offering.

During the quarter, our new US Product and Application Specialist began supporting customers with training and clinical implementation. She brings practical experience from more than 100 TSE procedures. A small but growing group of highly active clinics provides valuable experience that we can share with other users through training and ongoing support.

Building clinical evidence

In July, the retrospective equine study from the Norwegian University of Life Sciences was presented at the European College of Veterinary Surgeons' scientific meeting in Liverpool. The study involved 26 horses with 66 sarcoid lesions and reported 97% complete remission at eight-month follow-up. Twenty-three horses were treated with standing-sedation rather than general anesthesia.

Product development guided by clinical needs

Shelf-life testing has been completed, supporting a validated 36-month shelf life for treatment kits. This gives clinics greater flexibility when planning purchases and managing inventory. Our hardware upgrade program is also nearing completion, supporting longer treatment sessions and providing capacity for future software functions.

We are working to expand our range of probes and electrodes to improve access to tumors in anatomically difficult locations, including the nose, tongue and deeper parts of the oral cavity. This includes evaluating smaller instruments and potential supplier collaborations, with compatibility, quality and clinical usability guiding the work.

Across our R&D activities, we remain committed to the safety and quality standards that guide our Human Care development. These same principles underpin our work in Animal Care, and we will not compromise them as we develop new instruments and expand the platform.

Word from the CEO cont'd

Continued development in Human Care

Human Care remains part of the Group's long-term value potential, with India as the principal market for clinical development. Recruitment in the ongoing study has progressed more slowly than expected. We continue to discuss additional clinical work with Tata Memorial and evaluate a focused, sponsored study, subject to funding and an agreed clinical plan.

Priorities for the coming quarters

Our immediate priorities are to turn our expanded commercial reach into new installations and help more clinics develop regular treatment activity. We are also assessing how to strengthen technical services, logistics and administration in North America, our largest commercial market. Any expansion will be pace to available funding.

Careful cost control and financing remain central to our planning. We continue to evaluate funding options to support commercial development and a selection of clinical projects. Achieving positive cash flow at Group level remains a key objective.

The growth in treatment kit sales gives me confidence in the value that clinics see in TSE. Together with our expanded sales capacity and ongoing key account discussions, this provides a foundation for further growth.

I would like to thank our employees, clinical partners, customers and shareholders for their continued commitment and support.

Mohan Frick – CEO Neem's Hill AB (publ)



About the Company

Neem's Hill AB (publ), corporate registration number 556937-9547, formerly Scandinavian ChemoTech AB (publ), is a listed holding, investment, and development company operating within veterinary medicine, human medicine, and related technologies.

The Company's activities include business development and organizational consulting for operations within these fields. Neem's Hill also owns and manages shares, ownership interests, securities, intellectual property, and other real and personal property, and conducts activities compatible with these purposes.

Neem's Hill was founded in Lund, Sweden, in 2015 by Mohan Frick, Dr. Göran Hellers, and Professor Emeritus Bertil Persson, who is widely recognized for his pioneering work within electroporation.

The Group combines experience in medical technology, radiation physics, surgical oncology, clinical development, product development, regulatory affairs, business development, and international commercialization.

Neem's Hill's role is to establish, develop, own and manage investments, innovations, and businesses that address important clinical and commercial needs through medical technology, strong intellectual property, clinical development, and scalable business models.

Today, the Group is built around two distinct business areas and investments:

- Human Care
- Animal Care

Each business area has its own company structure, product platform, customer groups, clinical strategy, geographic market focus, and commercial organization.

Human Care is represented by Scandinavian ChemoTech and its IQwave™ product platform. The business area is primarily focused on establishing Tumor Specific Electroporation™ as a treatment option for head and neck cancer and other solid, tissue-based tumors, with a current clinical and commercial focus on India, Asia, and Southeast Asia.

Animal Care is represented by VQ Animal Care Inc., headquartered in the United States, and its vetIQure™ product platform. The business area focuses primarily on the North American and European veterinary markets and provides veterinary oncologists, surgeons, and other clinicians with a portable platform for treating tumors in companion animals and horses.

Both business areas currently use the Group's patented Tumor Specific Electroporation™ technology. TSE therefore represents an important shared technological and intellectual-property asset within Neem's Hill's current portfolio.

Neem's Hill's broader purpose is, however, to act as a holding-, investment-, and development company capable of establishing, acquiring, developing, and managing additional businesses, technologies, assets, and investments over time. Future investments do not necessarily need to be based on TSE, provided they are compatible with the Company's purpose and strategic focus within veterinary medicine, human medicine, and related technologies.

Tumor Specific Electroporation™

Tumor Specific Electroporation™ is a patented technology platform developed to enable more tumor-specific and tissue-preserving cancer treatment.

TSE is designed to increase the uptake of therapeutic molecules in cancerous tissue, allowing low doses of anticancer drugs to be concentrated more effectively within the treated tumor. This may enable treatment with substantially lower doses of chemotherapy than conventional systemic cancer treatment while reducing exposure to surrounding healthy tissue.

The technology is designed to promote apoptosis, or programmed cell death, while minimizing uncontrolled cell death, tissue destruction, and necrosis. Depending on the indication, tumor location, and individual patient requirements, TSE treatment can often be performed without general anaesthesia in both human and animal patients.

Conventional electroporation systems typically deliver a fixed and predetermined voltage. However, the electrical resistance of tissue may vary significantly between tumors, tissue types, patients, and different stages of treatment.

When the voltage remains static while tissue resistance changes, the resulting current may vary in an uncontrolled and unpredictable manner. Consequently, the total energy delivered to the tissue may also vary, increasing the risk of excessive energy delivery, tissue heating, coagulation, necrosis, and damage to surrounding healthy tissue.

TSE uses advanced hardware and software to monitor the electrical response of the tissue and dynamically adjusts the voltage throughout the pulse sequence. The system provides real-time feedback, treatment warnings, and integrated safety functions intended to keep the treating physician or veterinarian in control throughout the procedure.

By adapting the voltage to the response of the tissue, TSE is designed to provide more controlled electrical stimulation, promote effective and reversible electroporation, and reduce the risk of excessive current and uncontrolled energy delivery.

Technology and Patent portfolio

The TSE technology platform is protected through three principal patented product areas:

- The TSE pulse-generation system
- The handheld treatment probe
- The sterile treatment electrodes

The Group's granted patents protect essential elements of our technology, including:

- The characteristics and functions of the pulse generator responsible for generating the TSE pulse
- The handheld probe, which allows the treatment electrodes to be positioned and moved in different directions
- The ability to treat both large and small tumors, including tumors located in anatomically restricted areas
- Specially designed electrodes intended for treating deeper-seated tumors

Commercial Products and Business Model

Neem's Hill has developed two commercially viable product platforms within its current business areas:

- IQwave™ for human medicine within Human Care
- vetIQure™ for veterinary medicine within Animal Care

Both systems are portable and can be transported between hospitals, clinics, and treatment locations.

The business model is based primarily on revenues from the sale, leasing, or placement of the treatment systems, together with recurring sales of sterile single-use treatment kits and electrodes.

Commercialization is conducted through a combination of direct sales, distributors, clinical partnerships, reference centers, and Centers of Excellence.

Within Human Care, the Group has established distributor and commercial relationships in selected markets in Asia, Africa, and Europe.

Within Animal Care, commercial activities are primarily conducted directly in the United States and Western Europe. The Group also collaborates with leading veterinary institutions and specialist clinics, including Equitom in Belgium and the Royal Veterinary College in London.

Regulatory and Quality Management

In 2021, the Group obtained CE certification for the IQwave™ 3.0 electroporation system.

The system holds an EC certificate issued by ECM, Ente Certificazione Macchine, Italy, under the applicable European medical device regulatory framework.

The Group's quality management system is certified in accordance with ISO 13485:2016, Medical devices — Quality management systems — Requirements for regulatory purposes.

Human Care and Animal Care products are commercialized in accordance with the regulatory requirements applicable in each respective market.

Listing

Neem's Hill AB's Class B shares are listed on Nasdaq First North Growth Market in Stockholm under the ticker NEEMS B.

Redeye Nordic Growth AB is the Company's Certified Adviser.

Financial Information

Scope of the Report

This interim report covers the period 1 January – 30 September 2026. Figures in brackets indicate the outcome for the corresponding period last year. Amounts are stated in kSEK.

Sales & Results

Net sales amounted to 3,376 kSEK (3,324) in the third quarter. Total sales for the first nine months amounted to 9,466 kSEK (9,637). All sales originated from Animal Care. All sales in the Parent Company were sales to Group Companies.

Animal Care has short lead time from order to delivery, and most orders are delivered almost immediately.

Inventory adjustments resulted in positive COGS for the quarter.

Operating loss amounted to -1,097 kSEK (-1,065) for the third quarter and -4,460 kSEK (-4,322) for the first nine months.

Other external costs, -4,116 kSEK (-3,207) are higher than previous quarters due to additional sales and marketing capacity introduced since June, including costs for seasonal conferences in Europe and US.

One-off accrued costs for consultants and financial and legal advice also burdened the quarter.

Personnel costs continue to be lower in 2026 compared to 2025 as the Company currently has more consultants.

Net loss amounted to -1,291 kSEK (-1,267) for the third quarter. Accumulated net loss amounted to 5,486 kSEK (-5,532).

EBITDA amounted to -1,941 kSEK (-1,139) for the parent company, including Human Care and 892 kSEK (939) for Animal Care for the third quarter.

Currency Risk

The Company is exposed to fluctuations in a few currencies. There is therefore a risk that changes in exchange rates may affect the Company's results and financial position. The Group generates most of its revenue in USD, with a significant portion of its costs also in USD.

The exchange rate for 1 EUR is 11,33 SEK (11,06) and 1 USD is 9,98 (9,42) as of September 30 according to the Swedish central bank.

Customs duties and tariffs

The Group is exposed to tariffs and customs duties in several markets including USA. The Group complies with the applicable regulations and laws in the respective countries and tries to streamline deliveries to keep the associated costs down.

Investments

Investments in intangible non-current assets amounted to 3,030 kSEK (4,079) and mainly related to the activation of patents and costs associated with the CE marking. Investments made during the first nine months amounted to 150 kSEK (108).

The company reports internally accumulated intangible fixed assets. This means that all expenses related to production of an internally accrued intangible fixed asset, are capitalized and amortized during the asset's estimated lifespan, provided that certain criteria are met.

Accumulated tangible assets amounted to 153 kSEK (2).

Financial Position & Financing

Cash flow from operating activities amounted to -2,470 kSEK (-1,663) for the third quarter and for the first nine months it was -5,393 kSEK (-3,406).

Cash and cash equivalents amounted to 1,924 kSEK (4,290) as of September 30.

The company had loans of a total of 8,030 kSEK (6,567) from external lenders and board members as of September 30.

This includes an overdraft facility of 2,500 kSEK, of which 2,000 kSEK had been used and 500 kSEK remained as an overdraft by September 30.

A loan of 6,000 kSEK was granted by a large financial institution during the previous quarter. 3,000 kSEK of these are included in the total loan amount.

We continue to evaluate funding options to support commercial development and a selection of clinical projects.

Equity for the Group amounted to 133 kSEK (6,193) as of September 30.

Consequently, the Group's equity is less than half of its registered share capital. At the same time, the Parent Company's equity amounts to 20,381 kSEK, which exceeds half of the Parent Company's registered share capital.

The Board of Directors continuously monitors the Group's financial performance and capital structure and based on current conditions and available financing, assesses that operations can continue as planned.

Accounts Receivable

Accounts receivable amounted to 1,990 kSEK (2,260) at the end of the quarter.

Organization

The Group had 1 (1) employee and 8 dedicated consultants, of which 4 work full-time.

Research & Development

Development is run in-house in collaboration with external clinics and consultants. The development work is focused on new development and further refinement of the current product portfolio.

Insurance

Neem's Hill has corporate insurance. The insurance cover is subject to continuing evaluation, and the Board of Directors assesses that the corporate insurance is adapted to the current scope of the business.

Disputes

Neem's Hill is not a party to any legal dispute or arbitration. Nor is the Board aware of any circumstances that could lead to any such legal proceedings or arbitration being initiated.

Significant Risks & Uncertainties

The company's significant estimates and assessments are described in the Annual Report for 2025 in the Directors Report. No significant changes have occurred since then.

Conditions for Continued Operations

The financial information in this report has been prepared based on the assumption of going concern. The company has historically reported losses. In preparing the interim report, management and the Board of Directors have based their assumptions on existing cash and cash equivalents and expected financing through loans and new share issues as well as increased sales. When estimating future expenses, management has considered that certain expenses are under management's control and can thus be eliminated or postponed to the future. Depending on revenues, additional funding may be required to maintain operations for the next twelve months. Management is aware of uncertainties in the estimation of future cash flows as well as uncertainty in the financing of operations and is actively working on these issues. If the Group is unable to continue to operate for any reason, it may affect the Group's ability to realize the carrying amount of its assets, particularly related to capitalized expenditure for research and development, as well as to pay debts on a timely manner and to the amounts recorded in the Group's interim report.


Valuation of Intangible Assets

The reported capitalized expenditure for research and development is subject to management's impairment testing. The most critical assumption, evaluated by management, relates to whether the intangible asset is expected to generate future economic benefits, at least equivalent to the carrying amount of the intangible asset. Management's assessment is that the expected future cash flows are sufficient to justify the carrying amount of the intangible assets, which is why no write-down has been made. However, the valuation is based on and dependent on the conditions for continued operations.

Company information & Group structure

Neem's Hill AB (publ), 556937–9547 is the parent company of three wholly owned subsidiaries, Scandinavian ChemoTech AB (SE), VQ Animal Care (US) and Chemotech International (SG).

Group structure:



Disclaimer

This financial report contains statements that may be future-oriented estimates.

Predictions are valid only on the date they are made. All predictions are subject to uncertainty. In view of this, actual results may differ from those stated in this report.

Accounting Principles

The Company applies the Annual Accounts Act and the Swedish Accounting Standards Board's general guidelines BFNAR 2012:1 (K3) when preparing financial reports.

Audit Review

This interim report has not been reviewed by the Company's auditors.

The share

The number of shares on September 30 amounted to 26,215,169 of which 2,412,857 were Class A shares (voting rights 3) and 23,802,312 Class B shares (voting rights 1).

The Company has two ongoing subscription warrant programs: Series TO4 and TO5. Full exercise of all subscription warrants would result in 1,160,000

shares in the Company, corresponding to a dilution effect of approximately 4,8%

Shareholders

The four largest shareholders were CEO Mohan Frick, Avanza Pension, Anders and Britt-Marie Frick and BEngström Förvaltning AB, who together held a total of 34,34 % of capital and 44,06 % of votes as of September 30, 2026.

Largest owners September 30, 2026	No of A-shares	No of B-shares	No of shares Total	No of votes	Percent of capital	Percent of votes
1. Mohan Frick (private or through own company)	1 508 880	1 754 638	3 263 518	6 281 278	12,45%	20,24%
2. Avanza Pension	0	2 881 169	2 881 169	2 881 169	10,99%	9,28%
3. Anders and Britt-Marie Frick	590 546	942 945	1 533 491	2 714 583	5,85%	8,75%
4. B Engström Förvaltning AB	238 805	1 084 955	1 323 760	1 801 370	5,05%	5,80%
5. Tom Asplund	0	1 376 573	1 376 573	1 376 573	5,25%	4,43%
6. Martin Jerndal	0	901 273	901 273	901 273	3,44%	2,90%
7. Amitbir Singh Banga	0	900 000	900 000	900 000	3,43%	2,90%
7. Harbir Singh Banga	0	900 000	900 000	900 000	3,43%	2,90%
9. Nordnet Pensionsförsäkring	0	749 844	749 844	749 844	2,86%	2,42%
10. Elbema Fastigheter AB	0	554 880	554 880	554 880	2,12%	1,79%
Summa:	2 338 231	12 046 277	14 384 508	19 060 970	54,87%	61,41%
Övriga	74 626	11 756 035	11 830 661	11 979 913	45,13%	38,59%
Totalt	2 412 857	23 802 312	26 215 169	31 040 883	100,00%	100,00%

(Shareholders who are not owner-registered, but whose shares are invested in insurance policies and custody accounts are not included in this list)

Financial information

Unless otherwise stated, amounts are in KSEK (thousands of Swedish kronor)

Group income statement

	2026 Jul-Sep	2025 Jul-Sep	2026 Jan-Sep	2025 Jan-Sep	2025 Jan-Dec
Net sales	3 376	3 324	9 466	9 637	12 285
Work performed by the company for its own use and capitalized	0	0	0	0	0
Other operating income	7	9	188	93	101
Total operating income	3 383	3 333	9 654	9 730	12 386
Goods for resale	34	-340	-1 172	-1 611	-1 989
Other external costs	-4 116	-3 207	-10 817	-8 061	-11 476
Personnel costs	-326	-347	-958	-2 679	-3 149
Depreciation and write-downs	-48	-490	-1 049	-1 470	-1 973
Other operating expenses	-24	-14	-118	-231	-262
Total operating expenses	-4 480	-4 398	-14 114	-14 052	-18 849
Operating profit/loss	-1 097	-1 065	-4 460	-4 322	-6 463
Net financial items	-194	-202	-1 026	-1 210	-1 593
Profit/loss after financial items	-1 291	-1 267	-5 486	-5 532	-8 056
Taxes	-	-	-	-	-
Net profit/loss for the year	-1 291	-1 267	-5 486	-5 532	-8 056

Consolidated balance sheet

ASSETS	2026-09-30	2025-09-30	2025-12-31
<i>Fixed assets</i>			
Intangible assets	3 030	4 079	3 788
Tangible assets	153	2	119
Financial assets	160	156	155
Total fixed assets	3 343	4 237	4 062
<i>Current assets</i>			
Inventories	3 740	3 511	2 794
Current receivables	4 056	5 338	2 676
Cash and cash equivalents	1 924	4 290	3 668
Total current assets	9 720	13 139	9 138
TOTAL ASSETS	13 063	17 376	13 200
EQUITY AND LIABILITIES			
Equity	133	6 193	3 186
Long-term liabilities	3 000	0	0
Current liabilities	9 930	11 183	10 014
TOTAL EQUITY AND LIABILITIES	13 063	17 376	13 200

Financial Information cont'd

Unless otherwise stated, amounts are in KSEK (thousands of Swedish kronor)

Consolidated cash flow analysis

	2026 Jul-Sep	2025 Jul-Sep	2026 Jan-Sep	2025 Jan-Sep	2025 Jan-Dec
Cash flow from operating activities	-2 470	-1 663	-5 393	-3 406	-3 744
Cash flow from investing activities	-62	-107	-300	-98	-426
Cash flow from financing activities	3 000	5 543	3 949	6 845	6 889
Total cash flow	468	3 773	-1 744	3 341	2 719
Cash and cash equivalent at the beginning of the period	1 456	517	3 668	949	949
Exchange rate differences in cash and cash equivalents	0	0	0	0	0
Cash and cash equivalent at the end of the period	1 924	4 290	1 924	4 290	3 668

Change in group equity

	2026 Jul-Sep	2025 Jul-Sep	2026 Jan-Sep	2025 Jan-Sep	2025 Jan-Dec
Equity at the beginning of the period	1 520	2 193	3 186	5 980	5 980
New share issue, net	0	5 043	2 486	5 043	5 088
Exchange rate difference	-96	224	-53	702	174
Net profit/loss for the year	-1 291	-1 267	-5 486	-5 532	-8 056
Equity at end of the period	133	6 193	133	6 193	3 186

Group key figures

	2026 Jul-Sep	2025 Jul-Sep	2026 Jan-Sep	2025 Jan-Sep	2025 Jan-Dec
Earnings per share, SEK	-0,05	-0,05	-0,21	-0,24	-0,34
Equity per share, SEK	0,01	0,27	0,01	0,27	0,12
Average number of shares	26 215 169	23 343 978	25 766 261	23 343 978	24 026 115
Number of shares at end of period	26 215 169	23 343 978	26 215 169	23 343 978	26 215 169
Market price at the end of the period	2,85	7,12	2,85	7,12	5,02

Financial Information cont'd

Unless otherwise stated, amounts are in KSEK (thousands of Swedish kronor)

Parent company income statement

	2026 Jul-Sep	2025 Jul-Sep	2026 Jan-Sep	2025 Jan-Sep	2025 Jan-Dec
Net sales (to group companies)	1 620	312	2 125	2 241	5 870
Work performed by the company for its own use and capitalized	0	0	0	0	0
Other operating income	-353	4	30	35	1 495
Total operating income	1 267	316	2 155	2 276	7 365
Other external costs	-2 790	-1 673	-5 149	-4 352	-11 841
Personnel costs	-91	-134	-265	-874	-1 277
Depreciation and write-downs	-38	-489	-1 018	-1 469	-1 959
Other operating expenses	-16	-3	-44	-8	-21
Total operating expenses	-2 935	-2 299	-6 476	-6 703	-15 098
Operating profit/loss	-1 668	-1 983	-4 321	-4 427	-7 733
Net financial items	529	-825	545	-3 503	-4 265
Profit/loss after financial items	-1 139	-2 808	-3 776	-7 930	-11 998
Taxes	-	-	-	-	-
Net profit/loss for the year	-1 139	-2 808	-3 776	-7 930	-11 998

Parent company balance sheet

ASSETS	2026-09-30	2025-09-30	2025-12-31
<i>Fixed assets</i>			
Intangible assets	2 819	4 079	3 687
Tangible assets	0	0	0
Financial assets	100	100	100
Financial assets, group companies	22 199	24 379	21 398
Total fixed assets	25 118	28 558	25 185
<i>Current assets</i>			
Inventories	2 835	2 574	2 240
Current receivables, group companies	2 460	820	2 190
Current receivables	397	343	290
Cash and cash equivalents	127	3 608	863
Total current assets	5 819	7 345	5 583
TOTAL ASSETS	30 937	35 903	30 768
<i>EQUITY AND LIABILITIES</i>			
Equity	20 381	25 694	21 671
Long-term liabilities	3 000	0	0
Current liabilities, group companies	1	134	271
Current liabilities	7 555	10 075	8 826
TOTAL EQUITY AND LIABILITIES	30 937	35 903	30 768

Financial Information cont'd

Unless otherwise stated, amounts are in KSEK (thousands of Swedish kronor)

Group Income statement per business area

	Parent company & Human Care				Animal Care			
	2026 Jul-Sep	2025 Jul-Sep	2026 Jan-Sep	2025 Jan-Sep	2026 Jul-Sep	2025 Jul-Sep	2026 Jan-Sep	2025 Jan-Sep
Net sales	0	0	0	0	3 376	3 841	9 466	6 313
Other operating income	4	26	184	31	3	18	4	53
Total operating income	4	26	184	31	3 379	3 859	9 470	6 366
Goods for resale	0	0	0	0	34	-497	-1 172	-1 271
Other external costs	-1 600	-1 115	-4 055	-2 501	-2 516	-1 342	-6 762	-2 353
Personnel costs	-326	-36	-958	-790	0	-950	0	-1 542
Other operating expenses	-19	-14	-108	-22	-5	-131	-10	-195
Total operating expenses	-1 945	-1 165	-5 121	-3 313	-2 487	-2 920	-7 944	-5 361
EBITDA	-1 941	-1 139	-4 937	-3 282	892	939	1 526	1 005

Declaration

The Board of Directors and the CEO assures that the Interim Report Q3 2026 provides a fair overview of the Company's operations, position, and results, and describes significant risks and uncertainties faced by the Company.

The Interim Report Q3 2026 has not been reviewed by the Company's auditor.

Lund 27 October 2026

Robin Sukhia
Chairman of the Board

Rolf Ehrnström
Board Member

Bengt Engström
Board Member

Amitbir Singh Banga
Board Member

Mohan Frick
Board Member and CEO

Financial Calendar 2026

• Year-end report 2025	17 February 2026
• Annual report 2025	14 April 2026
• Interim report Q1 2026	28 April 2026
• Annual General Meeting	5 May 2026
• Interim report Q2 2026	11 August 2026
• Interim report Q3 2026	27 October 2026
• Year-end report 2026	23 February 2027

All financial reports are published on www.neemshill.com

For further information, please contact:

Mohan Frick, CEO

E-mail: ir@neemshill.com

Phone: + 46 (0) 10-218 93 00

Neem's Hill AB (publ)

Medicon Village
Scheeletorget 1, 223 63 Lund
010-218 93 00